COGNETIVITY NEUROSCIENCES LTD. Financials Cognetivity Neurosciences Ltd.
Equities
CGN
CA19243C1005
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.02 CAD | 0.00% |
|
+33.33% | +33.33% |
Valuation
| Fiscal Period: Januari | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Capitalization 1 | 18.32 | 9.893 | 43 | 41.88 | 21.26 |
| Enterprise Value (EV) 1 | 17.94 | 9.622 | 41.95 | 41.8 | 20.31 |
| P/E ratio | -4.14 x | -3.45 x | -18.6 x | -2.95 x | -2.86 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | 468,683,463 x |
| EV / Revenue | - | - | - | - | 447,667,262 x |
| EV / EBITDA | -4.39 x | -3.8 x | -17.5 x | -3.22 x | -3.23 x |
| EV / FCF | -9.28 x | -9.83 x | -23.3 x | -56.9 x | -4.89 x |
| FCF Yield | -10.8% | -10.2% | -4.3% | -1.76% | -20.5% |
| Price to Book | 38.2 x | -37.6 x | 49.8 x | -7.42 x | -2.15 x |
| Nbr of stocks (in thousands) | 42,601 | 49,466 | 70,488 | 79,015 | 85,049 |
| Reference price 2 | 0.4300 | 0.2000 | 0.6100 | 0.5300 | 0.2500 |
| Announcement Date | 5/29/19 | 6/1/20 | 5/31/21 | 6/3/22 | 6/9/23 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: January | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | 0.0454 |
| EBITDA 1 | -0.82 | -4.087 | -2.534 | -2.393 | -12.98 | -6.291 |
| EBIT 1 | -0.8214 | -4.091 | -2.543 | -2.405 | -13 | -6.315 |
| Operating Margin | - | - | - | - | - | -13,920.66% |
| Earnings before Tax (EBT) 1 | -1.496 | -4.193 | -2.66 | -1.926 | -13.13 | -7.434 |
| Net income 1 | -1.496 | -4.193 | -2.645 | -1.928 | -13.13 | -7.434 |
| Net margin | - | - | - | - | - | -16,386.31% |
| EPS 2 | -0.0506 | -0.1037 | -0.0580 | -0.0329 | -0.1797 | -0.0874 |
| Free Cash Flow 1 | -0.1954 | -1.932 | -0.979 | -1.802 | -0.7345 | -4.154 |
| FCF margin | - | - | - | - | - | -9,156.81% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 5/25/18 | 5/29/19 | 6/1/20 | 5/31/21 | 6/3/22 | 6/9/23 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: January | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | 0.0454 | 0.00417 | 0.0203 | 0.0292 |
| EBITDA 1 | -1.075 | -5.82 | -4.15 | -1.565 | -1.566 | -1.839 | -2.039 | -2.257 | -2.063 | -2.083 |
| EBIT | - | - | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 9/29/21 | 12/17/21 | 6/3/22 | 6/29/22 | 9/29/22 | 12/16/22 | 6/9/23 | 6/29/23 | 9/29/23 | 12/29/23 |
1CAD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: January | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 3.61 | 0.38 | 0.27 | 1.05 | 0.08 | 0.95 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -0.2 | -1.93 | -0.98 | -1.8 | -0.73 | -4.15 |
| ROE (net income / shareholders' equity) | -91% | -217% | -2,445% | -643% | 546% | 143% |
| ROA (Net income/ Total Assets) | -26.9% | -114% | -217% | -117% | -424% | -163% |
| Assets 1 | 5.569 | 3.666 | 1.218 | 1.652 | 3.095 | 4.552 |
| Book Value Per Share 2 | 0.1400 | 0.0100 | -0.0100 | 0.0100 | -0.0700 | -0.1200 |
| Cash Flow per Share 2 | 0.0100 | 0.0100 | 0.0100 | 0.0200 | 0.0200 | 0.0300 |
| Capex 1 | 0.01 | 0.02 | 0.02 | 0.02 | 0.06 | 0.02 |
| Capex / Sales | - | - | - | - | - | 51.76% |
| Announcement Date | 5/25/18 | 5/29/19 | 6/1/20 | 5/31/21 | 6/3/22 | 6/9/23 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +33.33% | 1.37M | |
| +4.71% | 32.58B | |
| +16.26% | 7.65B | |
| +21.60% | 3.92B | |
| -15.80% | 3.19B | |
| -27.19% | 1.26B | |
| -33.58% | 1.14B | |
| -33.74% | 926M | |
| +1.56% | 908M | |
| -23.93% | 859M |
- Stock Market
- Equities
- CGN Stock
- Financials Cognetivity Neurosciences Ltd.
